abstract
- This article considers the implications of reporting multiple measures of efficacy in studies of patients with rheumatoid arthritis (RA). A possible solution to the problems that result is the use of a pooled index which combines the individual outcome measures. The potential advantages and disadvantages of pooled indexes are discussed in the context of clinical trials in RA.